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ENGLISH SUMMARY 
Carbon monoxide (CO) is an extremely poisonous gas, without smell, taste or colour. 
Therefore, it is hard to detect without the use of electronic CO alarms. Normally, only 
insignificant concentrations are present in the air we breathe, however, in 
connection with incomplete combustion of organic material, the concentration can 
rise markedly. Thus, smoke from fire and exhaust gas from cars (although less after 
the introduction of the catalytic converter), cause CO poisoning. The toxicity of CO is 
primarily based on the high affinity to ferric and ferrous iron which is found in several 
essential molecules in the human body i.e. hemoglobin, myoglobin and cytochrome 
c oxidase (complex IV). Of other toxic effects that should be mentioned are induction 
of inflammation, and increase in the formation of reactive oxygen species, which 
may cause damage to the cellular proteins i.e. DNA. These toxic reactions result in 
acute symptoms i.e. headache, dizziness, dyspnea, unconsciousness, heart failure 
and ultimately death. The treatment of CO poisoning has not changed much during 
the last 50-60 years and is entirely based on inhalation of 100% oxygen, either at 
normobaric conditions (NBO) or hyperbaric conditions (HBO) which in Denmark is 
provided by Rigshospitalet in Copenhagen. Extracorporeal membrane oxygenation 
(ECMO) is primarily used in the treatment of patients suffering from cardiac or 
pulmonary failure. By oxygenation of the blood outside the body and/or supporting 
cardiac function, it may be possible to buy time to execute intervention or to wait 
for the affected organ to restitute and regain its function.  
The overall aim of this PhD project was to describe the extend of CO poisoning in 
Denmark. Additionally, to increase our knowledge regarding the acute management 
with focus on 1) the possibilities to use ECMO in the treatment of severely CO 
intoxicated patients and 2) use this technique during airborne transportation of 
patients over long distances using fixed wing aircrafts. 
To gain insight into the above mentioned issues, an epidemiological study and two 
experimental studies using animal models, were performed. 
In study 1, the incidence of CO poisoning in Denmark, during the period from 1995-
2015, was evaluated, with focus on, how potential co-morbidities are associated to 
mortality. Additionally, evaluation of how HBO treatment was associated with 
survival was done. This study was a retrospective follow-up study using several 
databases at Statistics Denmark. In study 2 and study 3, experimental animal models 
(pigs) were utilized. In Study 2, 12 pigs were used. They were poisoned with CO until 
cardiac failure, and then they were randomized to either ventilator treatment using 
FiO2 at 100% or ECMO treatment. Simultaneously the pulmonary vascular resistance 
(PVR) was measured and lung biopsies were secured in order to reveal any potential 
damage to the lung tissue. Study 3 was a feasibility study, in which a pig was 
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poisoned with CO and then subjected to a flight at 8,000 feet, using a Hercules C130J 
from the Danish Airforce. During flight, cardiac arrest was induced in the pig followed 
by testing of the feasibility of performing in air cannulation. 
In Study 1, data from 22,930 persons was analysed. Approximately 1,000 persons are 
poisoned with CO each year and approximately 100 persons die from CO poisoning 
annually. The overall mortality was 9.2%, of which the majority did not reach a 
hospital alive (85%). Among the patients who survived the initial 30 days after 
poisoning, no difference in survival was found when comparing those who received 
HBO treatment to those who did not, once various co-morbidities were taken into 
account. The comorbidities that were associated with increased mortality, were in 
general those typically associated to impaired cognitive or physical condition. Among 
those who died from exposure to gas and not fire smoke, 98% were intentional 
poisonings.  
In study 2, a significantly increased survival among the research animals in the group 
treated with ECMO was found. All six pigs survived beyond complete discontinuation 
of ECMO. Contrary, only one pig in the ventilator group survived, while the five 
others went into cardiac arrest that could not be reversed using conventional 
advances resuscitation methods. However, after these resuscitation efforts were 
abandoned, four out of these five pigs were then resuscitated using ECMO treatment 
after which they could be weaned completely. Even though a very high arterial 
oxygen pressure (PaO2) was reached, when using ECMO treatment, this did not 
reflect as a decrease in the half-life of HbCO. There was no correlation between CO 
poisoning and the PVR and also no histological changes in the lung tissue samples. 
In study 3, it was demonstrated that performing a flight with a CO poisoned pig in a 
Hercules C130J aircraft is possible. Additionally it was demonstrated, apparently as 
a world first, that it is possible to perform cannulation and initiate ECMO treatment 
during flight.  
Further research is required to explore, how ECMO treatment can be implemented 
in the acute treatment of CO poisoning. By using ECMO treatment during flight, or 
as a possible rescue therapy, we might be able to perform fixed wing airborne 
transportation of patients that otherwise would have been too critically ill for aerial 
transportation. 
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DANSK RESUME 
Kulilte er en yderst giftig gasart, som hverken har nogen lugt, smag eller farve. Det 
er derfor svært at opdage den uden brug af elektroniske alarmer. Normalt er der kun 
ubetydelige mængder af kulilte i den luft vi indånder, men i forbindelse med 
ufuldstændig forbrænding af organiske materialer kan koncentrationen stige 
markant. Således vil bl.a. røg fra ild og udstødningsgas fra biler (dog i mindre grad 
efter indførelse af katalysatoren), kunne medføre forgiftning. Kuliltes toksicitet 
skyldes primært den store affinitet til jern-ioner som findes i flere essentielle 
molekyler af betydning for homoeostasen, såsom hæmoglobin, myoglobin og 
cytocrom c oxidase (kompleks IV). Af andre effekter kan nævnes induktion af 
inflammation, samt dannelse af reaktive oxygen species (ROS), der medfører 
dannelse af frie radikaler, som potentielt kan forårsage skade på arvemassen (DNA). 
De toksiske skadevirkninger medfører i det akutte forløb symptomer som hovedpine, 
svimmelhed, åndedrætsbesvær, bevidstløshed, hjertesvigt og kan i yderste 
konsekvens medføre døden. Behandlingen af kulilteforgiftning har ikke ændret sig 
nævneværdigt gennem de seneste 50-60 år og består af inhalation af 100% ilt, enten 
ved normalt tryk (NBO) eller ved højt tryk i et trykkammer (HBO) som findes på 
Rigshospitalet. Ekstrakorporal cirkulation (ECMO) bliver almindeligvis anvendt til 
behandling af patienter med hjerte- eller lungesvigt. Ved at ilte blodet uden for 
kroppen/overtage hjertets funktion kan man købe sig tid til at foretage intervention, 
eller til at det påvirkede organ kan komme sig og varetage sin funktion igen.  
De overordnede mål med dette ph.d. projekt var at beskrive omfanget af 
kulilteforgiftning i Danmark. Desuden at øge vores viden omkring aspekter ved den 
akutte behandling med hovedvægt på at undersøge 1) mulighederne for brug af 
ECMO som behandling af svært kulilteforgiftede patienter og 2) anvendelse af denne 
teknik ved luftbåren transport af patienterne over længere distancer med fly. 
For at belyse ovenstående problematikker udførte vi et registerbaseret 
epidemiologisk studie samt to dyreeksperimentelle studier. 
I studie 1, kiggede vi på forekomsten af kulilteforgiftning i Danmark i perioden 1995-
2015 med særligt fokus på, hvorledes eventuelle co-morbiditeter indvirkede på 
mortaliteten. Desuden kiggede vi også på, hvorledes HBO-behandling var associeret 
med overlevelsen. Der er tale om et retrospektivt follow-up studie med anvendelse 
af forskellige databaser hos Danmarks Statistik. I studie 2 samt studie 3 anvendte vi 
en dyremodel med grise. I studie 2 indgik 12 grise som blev forgiftet med kulilte indtil 
de fik hjertesvigt, hvorefter de blev randomiseret til enten respiratorbehandling med 
100% ilt eller ECMO-behandling. Samtidig målte vi modstanden i lungekredsløbet, 
samt tog lungebiopsier for at afsløre eventuelle histologiske alveoleskader. Studie 3 
var et feasibility studie, hvor vi kulilteforgiftede en gris og derefter foretog en 
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flyvning i 8.000 fod i et Hercules C130J fly fra Forsvaret. Undervejs inducerede vi et 
hjertestop på grisen, hvorefter vi testede om kanylering under flyvning var praktisk 
muligt. 
I studie 1 analyserede vi data fra 22.930 personer. Vi fandt, at ca. 1000 personer 
bliver forgiftet med kulilte årligt i Danmark, og at ca. 100 personer dør om året som 
følge af kulilteforgiftning. Den samlede mortalitet var 9,2%, hvoraf størsteparten 
blev erklæret døde uden at komme på hospitalet (85%). Blandt dem, der overlevede 
de første 30 dage efter forgiftningen, var der ikke nogen forskel på overlevelsen 
blandt dem, der modtog HBO-behandling vs. dem, som ikke fik HBO behandling, når 
man korrigerede for diverse co-morbiditeter. De co-morbiditeter der vat associeret 
med øget dødelighed var dem som man typisk forbinder med dårlig kognitiv eller 
fysisk funktion. Blandt dem, som omkom, hvor eksponeringskilden var gas og ikke 
røg, var 98 % selvmord.  
I studie 2 var der markant øget overlevelse blandt de forsøgsdyr, der blev behandlet 
med ECMO. Alle 6 grise overlevede og kunne til sidst klare sig uden ECMO-støtte. 
Kun én gris i respiratorgruppen overlevede, mens resten fik hjertestop og ikke kunne 
genoplives med konventionel avanceret hjertelungeredning. Efter 
genoplivningsforsøg blev opgivet, lykkedes det dog, ved hjælp af ECMO, at få 4 ud af 
disse 5 grise til at overleve til et punkt, hvor også de kunne klare sig uden ECMO-
støtte. Selvom vi kunne opnå et meget højt ilttryk i blodet hos grisene ved 
anvendelse af ECMO, havde det ikke nogen gavnlig effekt på halveringstiden af 
HbCO. Vi fandt ikke en sammenhæng mellem forgiftning og modstanden i 
lungekredsløbet, og heller ikke nogen histologiske forandringer i lungevævet. 
I studie 3 demonstrerede vi, at det kan lade sig gøre at foretage en flyvning med en 
kulilteforgiftet gris i et Hercules C130J fly. Tillige demonstrerede vi, tilsyneladende 
som de første i verden, at det er muligt at foretage kanylering og igangsætte ECMO 
behandling under flyvning. 
Yderligere forskning er påkrævet for at undersøge, hvorledes ECMO-behandling kan 
implementeres i den akutte behandling af kulilteforgiftning. Ved at anvende ECMO-
behandling under flyvning, eller eventuelt have muligheden for at kanylere og starte 
ECMO-behandling undervejs, kan man potentielt flytte patienter, som ellers ville 
være for kritiske til transport med fly. 
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Long distance transportation of CO-poisoned patients on ECMO seems 
possible – a porcine feasibility study. Submitted to Air Medical Journal. 
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2 BACKGROUND 
2.1 CLINICAL ASPECTS OF CARBON MONOXIDE POISONING 
 
BIOCHEMISTRY 
Carbon monoxide (CO) consists of one carbon atom and one oxygen atom bound 
together via three covalent bonds (Figure 1.1). CO freezes at -205 °C and evaporates 
at -191.5 °C (1 atm) and therefore appears in the form of a gas under normal 
temperature and pressure conditions (3). CO has approximately the same density as 
the surrounding atmospheric air, and CO concentrations at sea level are 
approximately 0.04-0.12 parts per million volume (ppmv), depending on geography 
(highest in the northern hemisphere). Peak concentrations of approximately 0.2 
ppmv have been observed in winter (4). Higher concentrations of CO typically occur 
in proximity to sites with incomplete combustion of organic materials, particularly in 
the presence of a low oxygen concentration:  
CxHy + zO2  ->  aCO2 + bCO + cH2O + dH2 
Figure 2.1. Carbon monoxide molecule. 
CO binds strongly to both ferrous (Fe2+) and ferric (Fe3+) iron. This binding is the 
leading cause of its toxic properties, as these iron ions have essential functions in 
vital molecules in the human body, as described in the following sections. 
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HISTORY AND SOURCES OF CARBON MONOXIDE 
As long as humans have harnessed fire, the risk of CO poisoning has been imminent. 
The first written evidence of CO poisoning was recorded by Aristotle in the third 
century BC in a description of how animals react to fumes. He writes “They are 
destroyed, however, by these things, just as human beings are; i.e., as human beings 
get headaches from, and are often asphyxiated by, the fumes of charcoal, so the 
lower animals perish from the strong fumes of brimstone and bituminous 
substances” (5). The great Carthaginian conqueror Hannibal is said to have used CO 
to execute prisoners during the First Punic War in 264-241 BC by lighting coal inside 
enclosed bathing rooms (6). Indoor coal burning poisoned the Byzantine emperor 
Julian in approximately 350 AD and probably killed his successor Jovian in 364 (7). 
However, it was not until 1842 that the French chemist and surgeon Nicolas Leblanc 
identified CO as the poisonous component of coal gas (6). At approximately the turn 
of the twentieth century, the internal combustion engine became commercially 
available (8) and thus gave rise to a new source of CO poisoning. To this day, CO 
produced by internal combustion engines remains a significant source of poisoning, 
as these engines are found in a wide range of vehicles (9–11), sea vessels (12,13) and 
power tools/electric generators (14). Notably, diesel-fuelled engines pose a very low 
risk compared to gasoline-fuelled engines (15). Another important source of CO 
poisoning is fire, and several forensic studies suggest that CO is the major cause of 
mortality in fire-related deaths and that heat/burns are of minor importance (16,17). 
The last of the important sources of CO poisoning is residential heat appliances, 
either as a result of leakage of the gas supply or defective emission of the waste 
fumes created by the combustion of the gas/fuel used to generate the heat (18,19). 
The use of residential heat appliances parallels the increased number of cases of CO 
poisoning in winter (20,21). Smoking can increase the level of Hemoglobin-CO 
(COHb) in the blood (22). This increase is normally moderate, as indicated by the 
results of a non-invasive CO-oximetry screen in an emergency department in the US 
reported in 2008 by Suner et al. (23). Notably, 10,856 patients were screened and 
presented average COHb levels of 5.17% (± 3.78) among smokers and 2.9% (± 2.76) 
among non-smokers. However, in some cases, much higher COHb levels occur as a 
result of smoking (24) and causal reports of COHb levels of 35% exist (25). 
The rare sources of CO poisoning mentioned in the literature include defective liquid 
petroleum gas (LPG)-fuelled water heaters (26,27), water pipe smoking (28–30), and 
the mixing of formic acid with strong acids (31,32). Unfortunately, CO has also been 
used during warfare and was used in the genocide of Jews during World War II (33).  
As described above, the toxicity of CO has been well known for centuries. In the next 
section, I will describe the more specific biological mechanisms of poisoning.  
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TOXIC EFFECTS OF CO 
As mentioned above, CO binds tightly to ferrous and ferric iron, which is an 
important component of several essential molecules in the human body, leading to 
a range of toxic effects. One of these molecules is haemoglobin (Hb) (Figure 2.4a). 
The Hb molecule contains four haem groups, each with a ferrous iron atom, which, 
under normal conditions, is used to transport O2 from the lungs to the various tissues 
in the body and CO2 away from the tissue and back to the lungs. The crude affinity 
of CO for ferrous iron is approximately 100,000 times stronger than O2; however, 
when ferrous iron is integrated in the Hb molecule this ratio is reduced by a factor of 
approximately 1,000. This strong affinity was first suspected by C. Bernard in 1857 
(34) and confirmed by J.S. Haldane (Figure 2.2a) in 1895 (35) in a study where he also 
noticed that the introduction of oxygen to organisms subjected to CO poisoning 
might improve the condition. Later, the binding of Hb and CO was described in more 
detail by C. Douglas and J.S. Haldane and his son J.B.S Haldane (Figure 2.2b) in 1927 
(36), when they constructed a Hb-CO dissociation curve illustrating how the amount 
of inspired oxygen is related to the saturation of Hb with CO (Figure 2.3a).  
 
Figure 2.2. a) J.S. Haldane (1910) and b) his son J.B.S. Haldane (1914). 
In the equilibrium that describes of the formation of HbO2 and HbCO (HbO2 + CO ⇌ 
HbCO + O2), only small concentrations of CO increase the formation of HbCO, 
whereas increase in the percentage of inspired oxygen facilitates the desaturation of 
CO from Hb (Figure 2.3b). The authors also discovered a leftward shift in the oxygen-
Hb dissociation curve in the presence of CO. This shift (the Haldane shift) impairs 
oxygen dissociation from Hb in tissues when Hb is partially saturated with CO.  
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Figure 2.3. a) The relation between the binding of CO to Hb depends on the concentration of inspired CO 
in two humans (upper curves) and two mice (lower curves). b) The relationship between the saturation of 
Hb with CO depends on the percentage of inspired oxygen when the CO concentration is constant (below 
0.1%) in a human (upper curve) and mice (lower two curves) Doulgas C. & Haldane J.S., 1912. 
As only 2% of the oxygen content in the blood is dissolved in the plasma (37) at a 
normal temperature/pressure, the expanded oxygen-carrying capacity of Hb is 
essential to ensure normoxic conditions in the tissues. When the oxygen-carrying 
capacity of Hb is reduced by competitive CO binding, sufficient tissue oxygenation is 
compromised. The binding of CO to Hb is approximately 210 times stronger than 
oxygen (38).  
Figure 2.4. a) Structure of the haemoglobin molecule, including the four haem-groups – marked by arrows 
(created by Bielabio). b) Structure of the myoglobin molecule.  
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J.B.S. Haldane noticed that the poisonous effects of CO seemed to extend beyond 
the effects on Hb. In a paper from 1927 (39), he stated “The movements of a moth 
and the germination of cress seed are inhibited by CO. The greater the partial 
pressure of 02 the more CO is required.” Neither moth nor cress use haemoglobin for 
oxygen transport. Therefore, he wrote in the paper: “It is concluded that cells contain 
a catalyst of oxidation which is poisoned by CO.” Several decades later, this catalyst 
was identified as cytochrome c oxidase (Figure 2.5) (40,41).  
 
Figure 2.5. Structure of the mitochondrial cytochrome c oxidase (Complex IV) – (courtesy of The European 
Bioinformatics Institute) 
Cytochrome c oxidase (complex IV) reduces oxygen, which forms water and pumps 
protons from the mitochondrial matrix into the intracellular space (Figure 2.6). 
Protons are used to produce ATP and are therefore essential in cellular energy 
metabolism, which is compromised by CO poisoning. Another well-known toxic 
agent that acts by inhibiting cytochrome c oxidase is cyanide (42).  
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Figure 2.6. Mitochondria. CO inhibits cytochrome c oxidase (complex IV) in the electron transport chain.  
The inhibitory effect of CO on cytochrome c oxidase extends beyond the 
normalization of the percentage of HbCO in blood and it is therefore suspected to 
play a role in the development of the long-term effects of CO poisoning (40).  
Myoglobin also contains a haem group with ferrous iron (Figure 2.4b) and transports 
oxygen in red muscle cells/heart muscle cells under normal conditions, where it 
carries oxygen to the mitochondria. Myoglobin also functions as an oxygen reservoir 
that may serve as a buffer under ischemic conditions. CO binds to the haem group 
with greater affinity than oxygen and thereby inhibits oxygen storage/transport, 
potentially leading to diminished contractility of heart muscle cells (43–45).  
CO intoxication induces an immune response by activating neutrophils (46) (47) and 
subsequently inducing the formation of reactive oxygen species (ROS), which 
facilitates the development of free radicals (48). CO poisoning also causes changes 
in the both neuronal and cardiac potassium ion channels, resulting in increased 
excitability (49). These changes, along with hypoxic damage and the inflammatory 
and immunological responses, may be the foundation for the neurological sequelae 
that are frequently associated with CO poisoning (50–53). 
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Regarding the impact of CO on pulmonary function, several papers have examined 
the effects of low concentrations of CO on pulmonary vascular resistance (PVR). Low 
concentrations of CO in inspired air reduce the pulmonary pressure by decreasing 
pulmonary vascular resistance (54–56). In cases of severe CO poisoning, damage to 
the epithelial layer of the alveoli have been described. In a paper by Fein et al., the 
authors discovered increased alveolar epithelial permeability following CO 
intoxication in a rabbit model that potentially caused pulmonary oedema and 
thereby decreased gas exchange (57). This finding is supported by a case report from 
1980 (58). However, compared to the number of cases of CO poisoning, pulmonary 
oedema is not frequently described. Further information about the effects of severe 
CO poisoning on the pulmonary circulation, PVR and the alveoli is needed to obtain 
a better understanding of the harmful effects of CO. 
CO poisoning results in a prominent risk of developing acute heart failure (59–61), 
and cardiac arrest which has a very high mortality rate. This was demonstrated in a 
study performed in 2001 that included 18 patients suffering from cardiac arrest (62). 
Despite extensive efforts, including HBO treatment, all patents died. Additionally, 
long-term cardiac effects have been reported, such as arrhythmias (63) and major 
adverse cardiovascular events (64).  
Symptoms associated with acute CO intoxication include headache, vertigo, nausea, 
visual impairment, palpitations, loss of consciousness, and coma, and can ultimately 
lead to death (65). In addition to the risk of imminent death, CO poisoned patients 
experience an increased risk of developing neurological symptoms i.e., dementia 
(66), extrapyramidal symptoms (53), and encephalopathy (67). Long-term survival is 
also decreased following CO poisoning (68). 
 
CURRENT TREATMENT FOR CO INTOXICATION 
Current treatment is generally based on increasing the oxygen supply for two main 
reasons: 1) to increase oxygen delivery to the tissues and 2) to increase the 
dissociation of CO from Hb and thereby increase the elimination of CO (69). 
J.S. Haldane was a pioneer in the treatment of CO poisoning. In a paper from 1895, 
he reported the possible benefits of using oxygen to treat CO poisoning in an animal 
experiment using mice (70). He also introduced the idea of using hyperbaric oxygen 
when he showed that rats survived CO poisoning when they were placed in a 
chamber containing oxygen at a pressure of 2 atmospheres. Furthermore, he also 
developed equipment for NBO (Figure 2.7) (1). The first application of the HBO to 
treat a patient with CO poisoning occurred in 1960 (71). 
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Figure 2.7. Normobaric oxygen therapy in 1917, J.S. Haldane (1)  
Under normobaric conditions, the administration of oxygen reduces the HbCO half-
life from approximately 320 minutes to 74 minutes (69), and an HBO treatment 
further reduces this value to approximately 20 minutes (47). Nevertheless, the 
effects of this reduction on mortality/morbidity are not completely evident. In a 
Cochrane review from 2011, the authors performed a meta-analysis of six previously 
published randomized controlled trials examining neurological sequelae and 
concluded that “Existing randomized trials do not establish whether the 
administration of HBO to patients with carbon monoxide poisoning reduces the 
incidence of adverse neurologic outcomes” (72). Although evidence supporting the 
opposite conclusion has been reported (73), a recent study from 2018 involving 
25,737 patients in Taiwan actually identified an increased risk of neurological 
sequelae, even after considering co-morbidities (74). Only one published 
retrospective study claims that HBO treatment is associated with decreased 
mortality (acute and 1-year) (75). Additional randomized controlled trials are needed 
to clarify the effects of HBO treatment on both the mortality and morbidity of 
patients with CO poisoning. 
No broadly accepted guidelines are available for the indications to offer HBO 
treatment (76). This limitation, along with the use of different protocols for 
treatment and the delay in the initiation of HBO treatment due to logistic challenges, 
may explain some of the inconsistencies in the reported benefits of HBO treatment. 
In Denmark, the criteria for offering HBO are (77): neurological symptoms that are 
more severe than an ordinary headache, a patient who is or has been unconscious, 
the presence of cardiac arrhythmias or decreased cardiac function, an HbCO level 
greater than 25% measured at any point, and pregnant patients. Although a 
hyperbaric chamber exists in Aarhus, HBO therapy is primarily performed at 
Rigshospitalet in Copenhagen. 
 
15 
Hyperbaric oxygen therapy has been reported to be associated with adverse events, 
such as pulmonary oedema, barotrauma and seizures (78,79), and requires the 
patient to be cooperative. Additionally, the access to HBO therapy for the individual 
patient may be limited by geographical restrictions, as HBO typically is only offered 
at selected medical facilities within each country.  
Several other strategies aiming to increase CO elimination have been proposed. 
Corbogen, a gas mixture of oxygen and 5-10% CO2 may have the potential to 
decrease the COHb half-life to a similar extent as HBO (80). Carbon dioxide does not 
bind to Hb in the same way as oxygen, as it is bound to the protein chains of the Hb 
molecule rather than the ferrous iron of the haem group. As a result, carbon dioxide 
does not compete with oxygen in this binding process. Based on the capabilities of 
CO2 to increase the elimination of CO, exercise has been shown to significantly 
decrease the CO half-life in patients with moderate CO poisoning (81). In an animal 
study, ECMO3 (ECMO using ozone) treatment has also been shown to decrease the 
half-life of CO (82). Another animal study reported the doubling of the CO 
elimination rate following exposure to light with a wavelength of 532-628 nm (83). 
Finally, the use of antioxidants to minimize the effects of ROS has also been 
suggested as part of the treatment for CO poisoning (50). 
Altogether, the treatment for CO poisoning has not changed substantially during the 
last 50-60 years. With our new and improved understanding of the toxic mechanisms 
of CO, we now have increased opportunities to search for more effective treatment 
protocols both in the acute phase of poisoning and strategies that will diminish the 
subsequent neurological impacts. The administration of ECMO in the initial phase of 
treatment may be a piece of this puzzle.  
 
2.2 EPIDEMIOLOGY OF CO POISONING 
 
EPIDEMIOLOGY WORLDWIDE 
CO poisoning is regarded as the most common form of poisoning (84,85). In the US, 
approximately 50,000 cases of CO poisoning result in visits to emergency 
departments each year (86). This value equals an incidence of approximately 16 
cases per 100,000 people/year. The annual number of deaths was estimated to be 
2,700 in a paper from 2008. More recent studies suggest a decreasing trend, with 
1,245 deaths reported in 2014 (87). The decline was due to a significant reduction in 
the number of deaths caused by intentional CO poisoning. 
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In 2013, the World Health Organization (WHO) Regional Office for Europe published 
a paper regarding deaths caused by CO poisoning in 28 member states (88). They 
collected data regarding 140,490 deaths from 1980-2008. However, the reporting 
was very inconsistent between countries, as differences in coding and information 
were evident across registries and the death rate varied from 0.02 to 12.8 between 
countries. Six countries provided data regarding admissions caused by intoxication 
with CO. The total number was 31,473 in the study period, corresponding to an 
average rate of admissions of 2.33 per 100,000 people/year.  
In Asia, several studies regarding the epidemiology of CO poisoning have also been 
performed. In a study from Wuhan, China, 156 deaths caused by CO poisoning were 
reported from 2009-2014, corresponding to 0.5 per 100,000 population/year (20). 
Although the manner of death was analysed, information about admissions was not 
included in this study. Indoor charcoal burning resulting in CO poisoning has been an 
increasingly popular method of committing suicide in Taiwan and Hong Kong in 
recent years (89). In a paper from Taiwan released in 2015, the authors also 
examined factors (symptoms) associated with mortality (90). Shock exhibited the 
strongest association with increased mortality. Other significant factors included 
hypothermia, hepatitis, renal failure and coma. The overall mortality rate was 7.3% 
and HBO therapy was administered to 18.8% of patients. Another paper from Taiwan 
also assessed the demographics of CO poisoned patients and noticed a higher 
proportion of mental illnesses among female patients (91). In this study, 24.2% of 
the CO intoxicated patients were treated with HBO.  
The aforementioned studies used very different methods, yielding differences in the 
results. While these differences may simply reflect the differences in geography, 
health care systems, logistics and treatment protocols, more comprehensive studies 
will contribute to the total knowledge in this field. In particular, additional studies 
analysing the impacts of co-morbidities may help provide strategies to improve 
impact/diminish the effects of CO poisoning.  
 
EPIDEMIOLOGY IN DENMARK 
No comprehensive published studies regarding the epidemiology of CO poisoning in 
Denmark along with an exploration of co-morbidities exist. A national report from 
the Danish Health Institute published in 1995 established national guidelines for the 
treatment of CO poisoning (92). The authors used data from Statistics Denmark to 
estimate the total number of cases of CO poisoning in Denmark. One hundred ninety-
two patients were identified from the Cause of Death Registry, and 151 patients from 
the Danish National Patient Registry (DNPR) were admitted following CO exposure, 
of which 12 died (included in the 192 patients). The total number of patients was 331 
in 1992 and the mortality was 58%. The authors recommended HBO therapy for 
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severe cases of CO poisoning. In 2003, this report was reviewed and updated by the 
Danish Health Authority, but the recommendations were not changed (93). In 2000, 
20 patients were treated with HBO. In 2001, this number increased to 33. 
Other studies have a more specific forensic perspective. For example, a paper 
published by Nielsen et al. in 2014 focused on suicide by charcoal burning (94) as did 
Hansen et al. (95) in 2006. All deaths by poisoning in East Denmark from 1998-2002 
were examined in another Danish forensic study by Johansen et al. published in 2006 
(96). Of the non-narcotic-related deaths, 13% were caused by CO and/or cyanide 
n=57. This study also examined the manner of death (36 due to an accident, 12 due 
to suicide and 9 due to uncertain causes).  
A previous specific and significant source of CO poisoning in Denmark was Town Gas. 
Town Gas is a centrally produced gas distributed by gas lines to individual homes and 
is a method for providing fuel for heat/cooking in larger Danish cities. The CO content 
has decreased over time and was finally phased out completely in 2007. The number 
of homes using Town Gas has also decreased. Previously, the CO content in town gas 
caused numerous deaths each year. From 1950-1959, 407 deaths were attributed to 
CO from town gas (299 suicides, 90 accidents, and 18 homicides) (97). Another 
survey published in 2007 by Thomasen and Gregersen(18) examined CO-related 
deaths from 1995-1999 and identified 22 cases in which town gas caused death of a 
total of 449 non-fire-related CO poisoning cases. 
Altogether, none of the above studies provides an overview of the epidemiology of 
CO poisoning in Denmark and how it develops over time. No Danish studies consider 
co-morbidities in the evaluation of the mortality of CO poisoning. No studies 
investigating how psychiatric diseases are linked to CO poisoning have been 
published and only a few international studies investigating this connection exist 
(73,91,98). Thus, additional research studies investigating the impacts of various co-
morbidities, including psychiatric diseases, on the risk of CO poisoning and the 
subsequent mortality are required. Along with analyses of risk factors, the manner 
of death and the impact of treatment with HBO therapy, these studies will provide 
information that may be helpful in the management of CO intoxicated patients.  
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2.3 EXTRACORPOREAL TREATMENT OF CO POISONING 
 
ECMO BACKGROUND 
Extracorporeal Membrane Oxygenation (ECMO) describes the principle of creating 
an external circulation in which blood is oxygenized through a synthetic membrane. 
Several alternative terms for this technology exist and are often used 
interchangeably (99), such as extracorporeal life support (ECLS), cardiopulmonary 
support (CPS), and extracorporeal cardiopulmonary resuscitation (ECPR). A 
particular pumpless setup is termed pumpless extracorporeal lung assist (PECLA) or 
interventional lung assist (iLA) (Figure 2.8) (100).  
Depending on the condition of the patient, the setup can vary between a number of 
different modes (101,102). In the veno-arterial (VA) modality, blood is drawn from a 
vein and infused in an artery (Figure 2.8). This approach can be used when circulation 
or both circulation and respiration are insufficient. In the veno-venous (VV) modality, 
blood is both drawn and infused into a vein (Figure 2.8). Using dual lumen cannula, 
this setup can be applied to a single vein. VV type ECMO is used when respiratory 
impairment is the only indication. Finally, a pumpless modality exists that takes 
advantage of the natural arterial-venous pressure gradient to drive blood though an 
extracorporeal oxygenator. By definition, this modality requires sufficient cardiac 
function to be effective. In rare cases, some of the above modalities have been mixed 
(103). 
 
Figure 2.8. The three most common modes of extracorporeal circulation: veno-arterial (VA) mode, veno-
venous (VV) mode and pumpless setup. 
Extracorporeal circulation has evolved substantially over the last century. Since the 
early animal experiments using bubble oxygenators, the technique has advanced 
over film and rotating disc oxygenation into the membrane oxygenators used today, 
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which are actually based on hollow fibre mats (2,104). The continuous improvements 
in the performance of the oxygenators is illustrated in Figure 2.9. Simultaneously, 
innovations in technology regarding pumps, cannulas and the introduction of 
heparin-coated circuits have also contributed to the improvements in extracorporeal 
treatment (105).  
 
Figure 2.9. Improvements in the efficiency of oxygenators over time. The Y-axis shows the oxygen transfer 
per area per min. (2) 
Gibbon showcased the potential of extracorporeal oxygenation when he performed 
the first open heart procedure in 1953 to close an atrial septal defect (106). Since 
then, the use of extracorporeal circulation has become a standard procedure in open 
heart surgery. However, the first randomized controlled trial from 1979 did not 
recommend the use of ECMO for respiratory deficiencies (107). In the CESAR trial 
from 2008, conventional ventilator support was compared to ECMO in patients 
suffering from severe adult respiratory deficiency syndrome (ARDS). Here, a 
significant reduction in mortality/severe disability was observed. This finding kick-
started a noticeable increase in the use of ECMO and in further research regarding 
the use of ECMO (108). During the H1N1 flu epidemic of 2009-2010, ECMO was used 
to treat severe respiratory failure. In a meta-analysis from 2013 regarding the utility 
of ECMO for H1N1-infected patients, the authors concluded that ECMO is feasible 
and effective (109).  
In patients with cardiac failure, ECMO has proven to be an effective tool (110). The 
Extracorporeal Life Support Organization (ELSO) has collected data regarding the use 
of ECMO for various purposes since 1990. Of the 15,942 patients treated with ECMO 
for cardiac failure, 42% survived to discharge/transfer, while 29% of those placed on 
ECMO for ECPR survived to discharge/transfer (111). In patients with accidental 
hypothermia and circulatory/respiratory failure, ECMO treatment using the warming 
capabilities of the extracorporeal circulation has proved effective on several 
occasions (112–114). 
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In addition to the risk of infection, which is always present whenever the skin is 
penetrated, the ECMO treatment is associated with several complications, such as 
vascular complications, leg ischemia, bleeding, hyper-fibrinolysis, stroke, and air 
embolism (115).  
In the section above, it has been established how ECMO works, including its 
advantages and disadvantages. In the next section, I will discuss the effectiveness of 
ECMO as a treatment for CO poisoning. 
 
ECMO USE FOR CO INTOXICATED PATIENTS 
Only three case reports regarding the use of ECMO to treat CO poisoning exist. In a 
case report from 2009, a CO poisoned patient was subjected to treatment with 
ECMO (116). The intoxication (HbCO=21.1%) led to both respiratory and cardiac 
failure; thus, HBO treatment was impossible. Despite intubation and ventilation 
using FiO2 at 100%, the PaO2 was only 4.6 kPa. Therefore, VA-ECMO was established 
and increased the PaO2 to 40.0 kPa. Three days later, the patient was weaned from 
ECMO and became stable enough to discharge from the intensive care unit after an 
additional 2 days. A similar case was described by Teerapuncharoen et al. in 2015 
(84). A CO intoxicated (HbCO=13.6%) patient experiencing cardiopulmonary failure 
underwent VA-ECMO treatment that increased the blood oxygen content from 8.5 
kPa (on ventilator, FiO2=100%) to 40-65 kPa. The patient was discharged 30 days 
after admission without neurological sequelae and had regained normal lung 
function after 24 weeks. In a third case, VV-ECMO was performed on a patient 
suffering from both respiratory and circulatory insufficiency for 7 days (117). This 
patient also survived without neurological sequelae.  
In an animal study using rabbits (118) by Yin et al., ECMO3 (ozone instead of oxygen) 
exerted better effects than an oxygen treatment, with a faster reduction in HbCO 
levels.  
The case reports along with the animal study described above indicate that ECMO 
treatment could be advantageous for severe CO poisoning. Nevertheless, additional 
research to confirm this hypothesis is required before the treatment is generally 
recommended. One advantage is that mobile ECMO systems have been developed 
and may be used during transfer of the patient, or the ECMO device can be brought 
to the patient (119). 
In the next section, I will discuss the challenges in the aerial transport of patients, 
and why ECMO treatment may be beneficial in some cases. 
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2.4 ECMO FOR TREATMENT DURING FIXED WING AIRBORNE 
TRANSPORTATION 
 
CHALLENGES IN THE AERIAL TRANSPORT OF PATIENTS 
Occasionally, long-distance airborne transfer of patients is required when injured/ill 
patients are located in isolated geographical locations or when multiple casualties 
occur and local medical resources are depleted. Shorter distances can be covered 
using rotary wing aircraft (helicopter), but for long distances, fixed wing aircrafts 
(planes) are more efficient due to the higher speed and longer range of travel (120). 
Nonetheless, airborne transportation using a fixed wing aircraft can be challenging. 
The aircraft cabin, particularly in military aircrafts, represents a hostile environment 
for the patient and the crew (121). Furthermore, medical equipment, i.e., 
ventilators, may perform differently than at sea level conditions (122). Another 
factor that may influence medical equipment is vibrations, which habitually 
accompany airborne activities and may cause failure or malfunction. Vibrations have 
also been shown to increase muscle activity and thus oxygen consumption (123). 
Noise inhibits free communication and masks sound alarms that are capable of 
alerting medical personnel (124). Gravitational forces (G-forces) should be 
considered when placing the patient inside the cabin as the pooling of blood in the 
opposite direction of acceleration caused by G-forces (125) may exert devastating 
effects on the patient. However, the primary complicating factor is the decrease in 
air pressure that occurs with increasing altitude, as described by Boyle´s Law from 
1662: P1V1=P2V2. This decrease in air pressure leads to a corresponding reduction in 
the oxygen content. Most aircrafts prevent a decrease in air pressure by pressurizing 
the cabin, although the maximum level of pressurization is typically approximately 
80% of sea level pressure and equivalent to an altitude of 8000 feet (ft) (126). 
Weather, air traffic and fuel consumption are important factors (127), and if 
turbulence is a concern, altitudes of approximately 8,000-10,000 ft. are associated 
with less turbulence (128). When conducting a military aerial MEDEVAC, tactical 
considerations may take priority over the condition of the patient/staff. Altogether, 
the aforementioned factors may limit the possibilities of conducting an airborne 
MEDEVAC for critically ill patients (129).  
The Royal Danish Air Force (RDAF) possesses custom-made intensive care MEDEVAC 
modules that can be loaded into the cargo bay of the Hercules C130J aircraft. These 
modules limit the impacts of noise and vibration and additionally create a 
temperature-controlled, lighted and air conditioned environment for the medical 
staff and the patient (Fig 2.10). Nevertheless, the limitations of reduced pressure 
with increasing altitude and the impact of G-forces remain the same. We lack 
knowledge regarding the use of ECMO in these modules. 
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In the next section, I will discuss how ECMO has previously been used during fixed 
wing aircraft transport of patients. 
Figure 2.10. Loading of an intensive care module (MEDEVAC module) into a Hercules C-130J Aircraft (left 
image). The right images shows the interior of the module with patient bays along the walls. (Study 3) 
 
ECMO DURING THE TRANSFER OF PATIENTS USING FIXED WING AIRCRAFTS 
Several studies examining the use the use of both VV-ECMO and VA-ECMO during 
fixed wing flights have been published (130,131). The most comprehensive study 
regarding transfer of patients while on ECMO was published in in 2014 by Bryner et 
al. (132). However, of the 221 patients, only 25 were transported by fixed wing 
aircrafts, with the furthest transfer reaching 3,100 km. The only fatality among all 
221 patients occurred while the staff were preparing for takeoff prior to a fixed wing 
transfer. In a new French retrospective study published in 2018, the authors describe 
19 patients who were transferred from Reunion Island to Paris (approx. 10,000 km) 
for a heart transplant while undergoing treatment with VA-ECMO during the flight 
(133). No fatalities occurred during these long-distance transfers. In a military 
setting, Fang et al. evaluated the efforts of the Landstuhl Acute Lung Rescue Team 
(ALERT), a team undertaking the aerial transfer of military casualties suffering from 
severe pulmonary insufficiency and in need of extracorporeal assistance (119). Three 
patients were moved by fixed wing aircrafts while being subjected to extracorporeal 
support; one on pumpless (PECLA) support and two on VV-ECMO. The feasibility of 
long-distance PECLA had previously been reported in a porcine study by Kjærgaard 
et al. (134).  
None of the aforementioned publications initiated ECMO as a consequence of CO 
intoxication. Furthermore, in all cases, cannulation and the initiation of ECMO were 
completed prior to transfer. Accordingly, we lack knowledge regarding the in-flight 
use of ECMO for CO poisoned patients and the possibilities of performing 
cannulation while airborne. Several factors contribute to the complexity of 
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performing this surgical procedure during flight, from connectivity, compatibility and 
fastening of medical equipment to the MEDEVAC module, ergonomics of the patient 
bay, to the safety of the medical staff performing the procedure. All these factors 
must be tested before medical staff can consider performing this surgery in a real 
MEDEVAC scenario. 

 
25 
3 AIMS AND HYPOTHESIS 
The general aim of this thesis was to obtain insights into the epidemiology of CO- 
poisoning in Denmark and to develop a novel approach for the treatment of severely 
CO intoxicated patients using ECMO. Additionally, the feasibility of applying this 
ECMO treatment during fixed wing aerial transport of patients with severe CO 
intoxication was explored. Three studies were designed to achieve all of these goals. 
The aims of the individual studies were:  
1) To clarify the extent of CO poisoning, its mortality and factors contributing 
to mortality. 
 
2) To investigate the therapeutic effect of VA-ECMO following severe CO- 
poisoning in an experimental porcine model. We hypothesized that VA-
ECMO would improve survival. 
 
3) To demonstrate the feasibility of using ECMO as a potential en route 
therapy following severe CO poisoning in a porcine model and to explore 
the possibilities for VA cannulation and initiation of this treatment in flight. 
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4 MATERIALS AND METHODS 
In this section, I will introduce the registries used in Study 1. I will briefly describe the 
materials and methods used in all three studies included in this thesis. The 
methodologies of the individual studies are described in detail in the individual 
papers. Three studies were included in this thesis; one retrospective registry-based 
epidemiological study and two clinical experimental studies using a porcine model.  
 
4.1 STATISTICAL ANALYSES 
For data management in Study 1, the statistical software program SAS (version 9.4, 
SAS Institute, Cary, North Carolina, USA) was used. For the analyses in all three 
studies, the statistical software R (version 3.4.1) combined with RStudio (version 
1.0.153) were used. 
A chi2-test was utilized to evaluate differences between subgroups in the study 
population investigated in study 1 and an unpaired t-test was used to compare 
differences between treatment groups in Study 2. In Study 1, a Kaplan-Meier survival 
analysis was conducted along with the construction of a Cox regression model. We 
excluded data from patients who died within the first 30 days of CO exposure to 
reduce the selection bias introduced when deciding which patients were eligible for 
HBO treatment. 
The resource equation was used (E=total number of animals-number of treatment 
groups) to calculate an appropriate sample size for Study 2 (135,136). E between 10 
and 20 is considered sufficient. Adhering to the “Three Rs” ethical guidelines for 
animal research (137), E was set to 10; the total number of animals was 12, with 6 in 
each treatment group. A paired sample t-test was used when comparing the mean 
PaO2 at baseline with the mean PaO2 at time of cardiac failure. Regression analyses 
were performed to predict PaO2, PVR and lactate levels from HbCO levels.  
No specific statistical analyses were performed in Study 3. 
 
4.2 STUDY 1 
Study 1 was a retrospective observational study that compiled data from several 
databases in Statistics Denmark (approval: GEH-2014-013 I-Suite nr: 02731). When 
conducting registry-based studies in Denmark, researchers are not required to 
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obtain approval from an ethical committee or from the individuals included in the 
study.  
We collected data from 01.01.1995-31.12.2015. Prior to this time period, ICD coding 
was different and data from the National Prescription Registry were not available. 
The date of 31.12.2015 represents the latest date with completely updated registers.  
People living in Denmark are included in The Danish Civil Registration System (CRS), 
which was founded in 1968 (138,139). Each person is given an individual Civil 
Personal Register (CPR) identification number, which is used for all contacts with the 
public administration, including health services. This personal number can be used 
to blend information from numerous registries; however, as it is encrypted, the 
identification of an individual is not possible.  
 
THE DANISH NATIONAL PATIENT REGISTRY 
The Danish National Patient Registry (DNPR) contains information about contacts 
with hospitals and emergency rooms from 1978 to the present (140). Information 
regarding the character of the admission are logged, along with information 
regarding the diagnosis relevant to the current admission and procedures performed 
(including hyperbaric oxygen therapy). From 1994 to the present, this information 
was coded according to the WHO International Classification of Diseases version 10, 
ICD-10 (141).  
 
THE NATIONAL PRESCRIPTION REGISTRY 
Since 1994, the information about all drugs sold based on prescriptions in Denmark 
have been collected in this registry (142). In study 1, this registry was solely used to 
identify patients suffering from insulin-dependent diabetes.  
 
THE DANISH REGISTER OF CAUSES OF DEATH 
The Danish register of causes of death is very old, as the collection of information 
about the causes of death was initiated in 1875 (143). From 1970 to the present, the 
information has been registered in an electronic database using the ICD system, 
similar to the DNPR. The cause of death registry contains information about the time 
and place of death, manner of death, main cause of death and factors contributing 
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to death. The information is entered by the hospital doctor, the forensic medical 
examiner or the patient’s own general practitioner. 
The compilation of data from the registries mentioned above, based on a diagnosis 
of CO poisoning/smoke poisoning, was performed along with statistical analyses 
based on these data. 
 
4.3 STUDIES 2 AND 3 
Both Studies 2 and 3 were approved by the Danish Animal Experiments Inspectorate 
J.nr. 2016-15-0201-01064. After completing the experimental protocol, all animals 
were sacrificed by an injection of a lethal dose of pentobarbital. 
The use of a CO alarm was enforced in all studies involving CO gas to secure sufficient 
warning in case of a leak. Cardiac failure was defined as a decrease in cardiac output 
of 50%, and cardiac arrest was defined as a systolic blood pressure less than 25 
mmHg. In Study 2, the primary outcome was survival in the absence of 
extracorporeal circulation for at least 10 minutes without cardiopulmonary collapse. 
Secondary outcomes were changes in pulmonary vascular resistance (PVR) and 
damage to the lung tissue.  
Twelve female pigs (mean weight 48 kg) were included in Study 2. For an illustration 
of the setup, see Figure 4.2, and a picture of the actual setup is presented in Figure 
4.3. A similar setup was used in the Hangar at Aalborg Airbase in Study 3. Animals 
were poisoned until cardiac failure occurred. At this time point, the allocation to 
either ventilator treatment using an FiO2 of 100% or ECMO was revealed. If cardiac 
arrest occurred, it was treated using the 2015 guidelines from European 
Resuscitation Council (144). If cardiac arrest developed in the ventilator group and if 
no signs of improvement in the condition occurred within 10 min of resuscitation, 
then the ECMO treatment was also initiated in this group (Figure 4.1).  
 
Figure 4.1. Flow diagram of the experimental protocol.  
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Figure 4.2. Illustration of the flow of air/CO between the equipment and the research animal. 
Samples of lung tissue were obtained at baseline and at time of randomization. 
These samples were preserved in formalin and transported to the Department of 
Forensic Medicine, Aarhus University for histological analyses using basic 
haematoxylin & eosin (H&E) staining. 
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Figure 4.3. Experimental setup.  
In study 3, one female pig (Danish Landrace) weighing 39 kg was used. For the 
collection of arterial blood gas samples, we used a mobile unit (ABL90 FLEX-Series, 
Radiometer Medical, Brønshøj, Denmark) that was operated by technicians from 
Radiometer, Denmark. A sheath was placed in the femoral artery on the left side and 
a sheath was placed in the femoral vein on the right side.  
The ECMO setup consisted of a centrifugal pump (Rotaflow, Maquet, Rastatt, 
Germany), an oxygenator (QUADROX adult, Maquet, Rastatt, Germany), a 19 French 
venous Cannula (Medtronic, Minneapolis, Minnesota, US) and a 15 French arterial 
cannula (Novaport, Novalung, Heilbronn, Germany). During the treatment with 
ECMO, the oxygen flow was set to a rate of 2 L/min. The flow rate of blood through 
the external circulation was approximately 2 L/min.  
An ambulance from the Air Force transported the pig from the Biomedical Research 
Laboratory to a hangar at Aalborg Air Base. The pig was the poisoned using the same 
methods as described in study 2. Then, the pig was transferred to the aircraft 
(Hercules C-130J, Lockheed Martin, Bethesda, Maryland, USA) and placed inside the 
MEDEVAC module (Figure 4.4). Cardiac arrest was induced at an altitude of 8,000 ft. 
Then, chest compressions were performed while both arterial and venous cannula 
were placed using the Seldinger method via the sheaths that had previously been 
placed in the femoral blood vessels (Figure 4.4). ECMO was initiated once the 
cannulas were in place. Resuscitation continued with use of DC-shocks (Zoll Pro Pac 
MD, ZOLL Medical Corporation, Chelmsford, Massachusetts, US) and medication, in 
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accordance with 2015 guidelines from the European Resuscitation Council (144). 
Along the flight path, a short decrease in altitude to 2,500 ft was required for reasons 
not related to the experiment. Cardiac arrest was induced 50 minutes into the flight, 
and the total duration of the flight was two hours where, after which the aircraft 
returned to Aalborg Air Base and the pig was returned to the hangar. After 
completing the experiment, the pig was euthanized with an intravenous injection of 
a fatal dose of pentobarbital. 
Figure 4.4. The pig was placed in the centre of the module to enable access from all sides. Cannulation 
was performed during cardiac arrest and chest compressions. (Study 3)
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5 RESULTS 
In the sections below, I will present the results of each study. Further results are 
presented in the individual papers. 
 
5.1 STUDY 1 
In this study, a total of 22,930 patients suffering from CO intoxication were included. 
The total number of cases per year along with corresponding number of fatalities are 
illustrated in Figure 5.1. Corresponding rates are illustrated in Figure 1 of Study 1. Of 
the total patients, 1,792 (8%) were declared dead prior to hospitalization and 21,138 
(92%) patients were hospitalized. The total 30-day mortality rate was 9.2% 
(n=2,102). Nevertheless, the 30-day mortality rate was only 1.5% (n=310) among the 
patients who made it to a hospital alive. The median follow up time was 8.1 years.  
 
Figure 5.1. Overview of the total number of patients (light blue) and number of deaths per year (dark 
blue). Total number of cases= 22,930.  
Information about the manner of death was extracted for 1,957 patients. Subjects 
who committed suicide preferred using gas and not fire/smoke; of the 1,957 deaths, 
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1,132 deaths were caused by gas/vapours, with 91.1% of cases being intentional. Of 
the 1,957 deaths, 825 deaths were due to fire smoke, with only 7.2% of these being 
intentional.  
In the survival analysis, plots of the survival of patients who were hospitalized and 
survived for more than 30 days after CO poisoning were drawn. The patients were 
divided into two groups stratified by the administration of HBO treatment (Figure 
5.2). This analysis showed diverging survival lines that were significant at the 95% 
confidence interval after six years (p<0.001).  
Fig 5.2. Kaplan Meier plot of survival in groups stratified by treatment. Only patients who survived for 
more than 30 days were included. Light blue-/red areas depict 95% CIs. (Study 1) 
A forest plot of the Cox regression model is shown below (Figure 5.3). After adjusting 
for the effect of co-morbidities, the HBO treatment was no longer associated with 
increased mortality (HR=1.2, p=0.14). This trend was also observed for drug abuse 
(HR=1.1, p=0.35).  
Increasing age was strongly correlated with an increased risk of mortality in age 
group 3 (HR=3.2, p<0.001) and age group 4 (HR=15.5, p<0.001). Prior co-morbidities 
that were associated with increased mortality were alcohol abuse (HR=2.1, p<0.001), 
psychiatric disease (HR=1.5, p<0.001), arterial embolism (HR=1.5, p=0.01), COPD 
(HR=1.7, p<0.001), cerebrovascular disease (HR=1.5, p<0.001) and atrial fibrillation 
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(HR=2.3, p<0.001). Drug abuse (HR=1.1, p=0.35), stroke (HR=1.1, p=0.40), and 
gender (HR=0.96, p=0.32) were not significant predictors of mortality. 
 
Fig 5.3. Forest plot of the Cox proportional hazards model. Age group1=0-24.4 years, age group2 
(reference) =24.4-36.6 years, age group3=36.6-50.75 years, and age group 4=50.8+ years. COPD=chronic 
obstructive pulmonary disease. Lines illustrate 95% CIs. (Study 1) 
 
5.2 STUDY 2 
Only one of the six CO intoxicated pigs that were randomized to ventilator treatment 
with FiO2 at 100% survived. Five animals suffered from cardiac arrest (mean of 11.8 
minutes after randomization) and a return of spontaneous circulation (ROSC) was 
not obtained in any of these animals through conventional advanced resuscitation 
methods. However, after the application of VA-ECMO, ROSC was obtained in four of 
these animals (80%). All animals in the ECMO group survived, and only one animal 
suffered from cardiac arrest, however in this case, ROSC was obtained after 17 
minutes (Figure 5.4, Study 2).  
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Figure 5.4. Flow chart of outcomes. ECMO=extra corporeal membrane oxygenation, ROSC=return of 
spontaneous circulation. (Study 2) 
The mean time on extracorporeal circulation was 182.5 minutes (SD=63.5) in the 
ECMO group compared with 201.6 minutes (SD=63.5) in the ventilator group p=0.96.  
A significantly higher peak PaO2 was achieved in the ECMO group compared to the 
ventilator group (Figure 5.5, Study 2), p<0.001. 
  
Figure 5.5. Peak arterial pO2 values after treatment with extracorporeal membrane oxygenation (ECMO) 
or ventilator treatment was initiated. (Study 2) 
When examining the HbCO half-life (T1/2), no differences between groups were 
identified (Figure 5.6). Overall, the T1/2(HbCO) was 77.2 minutes (min), with a 
T1/2(HbCO) for the ECMO group of 86.0 min, and T1/2(HbCO) for the ventilator group 
of 70.0 min. This analysis is not included in Study 2. No significant difference was 
observed in the mean time required for HbCO levels to decrease to less than 10% 
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after intoxication: 123.7 minutes (SD=20) in the ECMO group compared with 163.7 
minutes (SD=15.2) in the ventilator group, p=0.56. 
 
Figure 5.6. Decrease in haemoglobin-CO (HbCO) levels over time in each treatment group. Light-coloured 
areas depict 95% CIs. ECMO= extracorporeal membrane circulation.  
Consistent changes were not observed in a comparison of lung tissue samples 
obtained at baseline and after severe CO intoxication (time of randomization). Fluid 
did not accumulate in the alveoli and inflammation was not detected. Figure 5.7 
illustrates the histology before/after CO poisoning.  
 
Figure 5.7. a) Haematoxylin & eosin-stained tissue samples obtained prior to CO intoxication (baseline, 
HbCO=3.6%) and b) at the time of randomization (HbCO=71.1%). Both images were captured at 100 X 
magnification.  
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5.3 STUDY 3 
Cannulation was successfully performed at 8,000 ft during cardiac arrest and 
followed by VA-ECMO treatment (Figures 5.8. and 5.9). The pulse generating sinus 
rhythm was restored upon defibrillation 29 min after cardiac arrest. Complete 
weaning was performed once on the ground again after being airborne for 127 min. 
Figure 5.8 depicts major events along with altitude, and Table 5.1 lists corresponding 
arterial blood gas values. Oxygenation during both ventilator treatment and VA-
ECMO treatment was high at 56-82 kPa and 40-58 kPa, respectively.  
 
Figure 5.8. Significant events are plotted over time and the corresponding altitude is represented with the 
red line. Arterial blood gas samples are listed in Table 5.2. Abbreviations: extracorporeal membrane 
oxygenation (ECMO) and return of spontaneous circulation (ROSC). (Study 3) 
 
Figure 5.9. Cannulation was performed and ECMO treatment was established. 
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Table 5.1. Major events, altitude, vital values and arterial blood gas results obtained during the 
experiment. (Study 3) 
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6 DISCUSSION 
Humans have suffered from CO poisoning since the discovery of fire. Additional 
sources of CO intoxication have emerged throughout history, and CO poisoning is 
now the most frequent form of poisoning in the US (19). Neurological sequelae and 
a high risk of mortality in patients with severe poisoning have inspired numerous 
studies in the field of CO poisoning. Despite this research has identified several toxic 
effects in addition to the strong binding of CO to Hb (75), these findings have yet to 
be utilized to develop new treatment strategies. Unknown factors contributing to 
the toxicity of CO may yet be discovered. Oxygen treatment has been the 
cornerstone treatment for CO poisoning over the last 50-60 years, and both NBO 
treatment and HBO treatment have been used (22). When oxygen is administered 
as HBO therapy, several limiting issues are introduced that potentially create a 
selection bias among patients who are treated. 
The aim of this PhD thesis was to investigate the extent of carbon monoxide 
poisoning in Denmark and important factors that may contribute to mortality. In 
addition, we also examined the effects of HBO therapy on survival. Furthermore, we 
introduced a systematic examination of the potential benefits of using 
extracorporeal circulation to treat severe CO poisoning with subsequent cardiac 
failure, and finally, we explored whether this approach could be utilized during a 
long-distance flight in a fixed wing aircraft. 
The main findings of study 1 were that CO poisoning is a frequent event that causes 
approximately 1000 contacts with the hospitals each year and results in 
approximately 100 deaths, of which 52% are caused by suicide. Several co-
morbidities, i.e., alcohol abuse, psychiatric diseases and atrial fibrillation along with 
increasing age, were associated with increased mortality. The data did not support 
the hypothesis that HBO treatment would result in improved survival after 
considering co-morbidities. In study 2, a markedly increased survival was observed 
when ECMO was administered to treat cardiogenic shock following CO poisoning. An 
increasing HbCO level was not associated with an increasing PVR, although it was 
associated with a decrease in PaO2. No changes were observed in the lung tissue 
samples obtained during various stages of CO poisoning. In study 3, the same ECMO 
treatment methods used in study 2 were applied to a CO poisoned pig during a flight 
in a fixed wing aircraft. Additionally, we successfully performed cannulation and 
established ECMO treatment while airborne. 
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6.1 EPIDEMIOLOGY OF CO POISONING 
In study 1, 10.8% of all patients included in this study had a prior diagnosis of alcohol 
abuse, and 8.6% had a previous diagnosis of psychiatric disease. Corresponding 
percentages from a study performed in Taiwan were 3.7% for alcohol abuse and 
32.1% for mental disorders (91). Large differences between our findings and the 
findings of the Taiwanese study are evident and may be based on differences in the 
registration of co-morbidities. The data included in the Taiwanese study utilized ICD-
9 coding (vs. ICD 10 coding in Study 1) and included “dependence of psychoactive 
substances” in the “mental disorder” group, whereas these patients were placed in 
the “drug abuse group” in the data described in Study 1. In addition, the diagnosis of 
the patient, along with the co-morbidities, may differ from Danish conditions. Other 
explanations for the discrepancies are differences in the health care infrastructure, 
source of exposure and severity of exposure. A study from Wuhan, China 
investigating the manner of death in 156 patients with CO poisoning reported the 
33% of these deaths were intentional, and the preferred source of exposure was 
from charcoal burning/gas installations (20). These findings are consistent with the 
findings from Study 1, in which the preferred method of committing suicide by CO 
poisoning was gas exposure (exposure 95%) and not fire-related exposure. The 
Taiwanese study reported a suicide percentage of 20.4; however, this number 
includes both suicides and attempts. In Study 1, 5.7% of the entire group of CO 
poisoned patients committed suicide, and 52% of all deaths occurred following 
intentional poisoning, which is higher than the value reported in Wuhan. Data are 
not available to investigate the percentage of suicide attempts in Study 1. Another 
paper by the same authors as the Taiwanese study using the same data examined a 
range of additional co-morbidities using a Cox proportional hazards regression 
analysis (73). Here, both similar and divergent results are noticed for alcohol abuse 
(HR of 2.06 in Study 1 vs. 1.69 in the Taiwanese study), stroke (HR of 1.14 in Study 1 
vs. 1.88), COPD (HR of 1.71 in Study 1 vs. 1.01) and psychiatric diseases/mental 
disorders (HR of 1.45 vs. 1.76). A higher percentage of patients were treated with 
HBO (28%) in the Taiwanese study than in Study 1 (4.5%). Again, conclusions based 
on these numbers are difficult to draw, as substantial differences in the methods, 
population and indications of HBO exist between studies.  
 
6.2 ECMO AS A TREATMENT FOR CO POISONING 
ECMO significantly improved the survival of animals with CO poisoning in the 
experimental porcine model. Potential survival benefits have previously been 
described in three case reports. In a case report by Wang et al., a 23-year-old male 
was admitted due to CO poisoning (145). The HbCO level was 21% at time of 
admission and the patient was semi-comatose. Despite endotracheal intubation and 
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ventilation using FiO2 at 100%, the PaO2 was only 6.0 kPa. These results are 
consistent with the decrease in PaO2 observed after CO poisoning (see Figure 2b in 
Study 2), and thus ventilator treatment may be insufficient. The authors observed 
“myocardial injury with myocardial suppression” and subsequent pulmonary 
oedema. VA-ECMO therapy increased the PaO2 from 4.6 kPa to 40.0 kPa. In our 
study, a much higher arterial PaO2 was observed in the ECMO group, and this finding 
is consistent with the case report. The patient described in the case report was 
successfully weaned after 3 days on ECMO treatment, but information about the 
neurological outcome was not provided. In a case report by Teerapuncharoen et al., 
a woman with CO poisoning exhibited a HbCO level of 13.6% several hours after the 
initiation of ventilator treatment with FiO2 at 100% (84). This patient developed 
circulatory collapse and was too unstable to be transferred to HBO therapy. Instead, 
VA-ECMO treatment was initiated and stabilized the circulation. The patient was 
weaned after four days and no neurological deficits were observed. In another case 
report by McCunn et al., a CO intoxicated victim was found unresponsive/apneic 
after a fire (117). Although the initially measured HbCO level of 40% decreased to 
9% and the patient was supported by a ventilator using an FiO2 at 100%, the PaO2 
was still very low (4.9 kPa). Since the patient was deemed too unstable to receive 
HBO treatment, extracorporeal lung assist (PECLA) was initiated and immediately 
improved the PaO2 to 12.7 kPa. The patient improved over time and was discharged 
without neurological impairments. These three case studies illustrate the diverse 
pathology and symptomatology of CO poisoning. For practical reasons, the pig was 
weaned from ECMO once the HbCO level was less than 10%. However, based on the 
clinical case studies, a much longer ECMO treatment is probably be needed. 
One of the main concerns regarding the use of ECMO for CO poisoning is the 
potential for poor neurological outcomes associated with cardiogenic shock and 
cerebral ischemia. Nevertheless, none of the three cases described above presented 
neurological deficits after treatment with ECMO. When considering ECMO therapy, 
the estimated time to the initiation of treatment should be considered, as an 
increase in the time to the initiation of ECMO is associated with worse neurological 
outcomes (146). Studies 2 and 3 did not investigate the neurological impacts of CO 
poisoning, and future studies should consider including this aspect into the protocol. 
The improved survival of the ECMO group may be due to the stabilization of the 
cardiac function, which other studies have reported to be affected by CO poisoning. 
Thirty-seven percent of patients included in the study by Garg et al. presented with 
“myocardial injury defined by elevated biomarkers and electrocardiographic (ECG) 
changes” (147). These findings are supported by Satran et al., who observed ischemic 
ECG changes in 30% of their patients (148). Two studies observed reversible cardiac 
stunning/dysfunction following CO poisoning (149,150). Thus, CO poisoning appears 
to be capable of causing transient cardiac ischemia, which may result in infarction if 
the CO intoxication is severe or persistent. ECMO treatment may be beneficial in this 
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regard, as it increases the oxygen content in the blood and minimizes cardiac stress 
and oxygen consumption through the support of the extracorporeal circulation. 
Are other benefits of ECMO treatment identified in this study explained by a 
reduction in T1/2(HbCO) and therefore sooner resolution? We speculated that the 
ECMO treatment would induce a higher PaO2 level than the use of pure oxygen 
administered through the ventilator. This hypothesis appeared to be validated 
(Figure 5.5, Study 2). However, as ventilator treatment was replaced with ECMO 
treatment in 83% of patients after conventional resuscitation had failed, may 
potentially favour ECMO treatment itself. Because the ECMO treatment increased 
the PaO2, a reasonable hypothesis is that this change would reduce the T1/2(HbCO). 
However, this hypothesis did not appear to be validated. In study 2, the T1/2(HbCO) 
was 77.2 minutes overall. This value corresponds well with the T1/2(HbCO) reported 
by Weaver et al. after the administration of 100% oxygen under normobaric 
conditions (151). The ECMO treatment did not exert an apparent beneficial effect on 
T1/2(HbCO) in the present study. However, our study (Study 2) was not specifically 
designed to investigate T1/2(HbCO) in detail. Thus, the ECMO treatment was 
administered to both groups, and no control group with an FiO2 of 21% was 
investigated. To the best of our knowledge, no studies describing T1/2(HbCO) during 
ECMO treatment have been reported. An animal study investigating the use of ozone 
(O3) in the extracorporeal circuit instead of oxygen for CO poisoned rabbits observed 
significantly lower HbCO levels 30 min after CO intoxication compared to the group 
treated with 100% FiO2 alone (82). No group was treated with ordinary ECMO in this 
study. A new, separate study should be designed with the main goal of properly 
exploring the potential beneficial effects of the ECMO treatment on the T1/2(HbCO).  
In the biopsies of the lung tissue, we were unable to identify any changes using 
histological examinations. We observed a decreased PaO2 and increased HbCO levels 
(please refer to Study 2, Figure 2b). This finding is consistent with the findings 
described in the three case reports mentioned above, where only an insufficient 
PaO2 was achieved, despite ventilator therapy with an FiO2 of 100%. This finding 
might be based on the increase in the diffusion barrier caused by CO poisoning. One 
cause of an increase in the diffusion barrier is pulmonary oedema. Pulmonary 
oedema has been reported to be associated with CO poisoning in several studies 
(152,153). The cause of this association may be thermal injuries (154), backward 
failure due to depressed cardiac activity, or tissue irritants present in the inhaled 
smoke, i.e., hydrogen chloride (HCl) (155). However, it cannot be excluded, that CO 
itself may cause tissue damage in the alveoli. In both studies 1 and 2, pure CO was 
administered, eliminating the risk of assessing damages caused by factors other than 
cardiac failure and CO itself. Despite the presence of cardiac failure, oedema was not 
observed in the tissue samples, potentially due to the short duration of cardiac 
failure, which was not a sufficient period for oedema to develop. Additionally, no 
changes in PVR were detected with increasing HbCO levels (Study 2, Figure 2c). 
Again, this lack of changes might have been due to the relatively short duration of 
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CO poisoning. Changes in the diffusion barrier, i.e., changes in surfactant levels or 
basement membrane that could cause diminished diffusion of oxygen (156), may not 
be detected by the examination of the tissue, as simple H&E staining was used. 
Moreover, immunological changes might have played a role, as suggested in the 
study by Pieri et al., who observed increased macrophage activity following CO- 
poisoning (157). These changes would not have been detected in the histological 
evaluation. Examinations using electron microscopy might have provided further 
insights.  
As we did not identify a correlation between increasing PVR and HbCO levels, Study 
2 does not support the hypothesis that cardiac failure, in cases of CO poisoning, is 
caused by increased PVR and subsequent backward failure. This finding is consistent 
with the results from a study by Zyckerbraun et al., who found that a low dose of CO 
reversed pulmonary arterial hypertension in rats (55).  
Several studies have reported the airborne transport of patients undergoing ECMO 
treatment using VV-ECMO, AV-ECMO and PECLA (119,133). However, during the 
literature review, studies reporting cannulation being performed while airborne 
were not identified. 
We chose to perform the feasibility test using a real aircraft that was actually flying 
during the experiment. In our opinion, this approach provided a realistic impression 
of the challenges associated with performing a flight with a real CO intoxicated 
patient. Another option would have been to use a hypobaric chamber to simulate 
the pressure conditions of the flight. This approach has previously been employed 
by Kjærgaard et al., and in a paper published in 2007, the authors described the use 
of interventional lung assist (iLA) during different modes of transportation, including 
fixed wing aircraft, and tests in a hypobaric chamber (158). The authors observed a 
decrease in PaO2 with increasing altitude, both real and simulated. This decrease is 
consistent with the findings from Study 3, as a clear increase in PaO2 was observed 
during a period of a decreased flying altitude (Study 3, Table 1, times: 14.00 and 
14.08). The authors repeated the experiment during an intercontinental flight once 
testing in the hypobaric chamber had been performed. The use of a hypobaric 
chamber has some advantages, as it is less costly, requires less logistic planning and 
the pressure can be controlled precisely for long periods of time. Nonetheless, 
factors that may complicate a flight, such as turbulence, G-forces and vibration, 
cannot be recreated, and the impact on both medical personnel and the patient can 
therefore not be tested. Additionally, the compatibility of the medical equipment 
with the aircraft is an important factor when evaluating feasibility and should 
therefore be tested during a real flight. 
With the exception of the aforementioned study, we did not identify papers 
describing the use of ECMO in a hypobaric chamber in either a clinical setting or in 
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an experimental setup. In addition, we were unable to identify any published papers 
examining the use of ECMO in a hyperbaric chamber.  
In Denmark, the Air Force has four intensive care MEDEVAC modules at its disposal 
(Figure 6.1), which are routinely used during aeromedical evacuation flights. 
Figure 6.1. Intensive care MEDEVAC module - exterior and interior (photos courtesy of Jean-Michel 
Ferrieux). 
These modules are prototype models that are not available in any other NATO 
country. Many countries within NATO have expanded their own capacity using many 
different approaches. The most common method is to install stretchers and medical 
equipment directly in the cargo bay of the aircraft (Figure 6.2), whereas a few other 
countries use the modular approach (159). No published overview on the MEDEVAC 
capabilities of the individual NATO countries exists. Advantages and disadvantages 
exist for both types of approaches. Modules create better environment for the 
patient and the staff; however, the loading and unloading of the modules makes the 
aircraft less flexible for use in other operational configurations. Additionally, 
MEDEVAC modules take up a large percentage of the cargo bay, and the total 
capacity of transporting patients is therefore diminished. Nevertheless, as described 
in chapter 2.4 of this thesis, the MEDEVAC modules have substantial advantages 
compared to the cargo bay when transporting a critically ill patient, both for the 
patient and the personnel.  
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Figure 6.2. The left image shows the interior of a US C-17 aircraft during an aeromedical evacuation of 
patients from Iraq to Germany. The right image shows a patient on veno-venous extracorporeal 
circulation transported in a C-17 aircraft from Japan to Hawaii.  
 
6.3 STRENGHTS AND LIMITATION OF THE STUDIES INCLUDED IN THIS 
THESIS 
A strength of study 1 is that a large number of patients, approximately 23,000 
persons, were included, and the median follow up time was relatively long, 8.1 years. 
Notably, Denmark is a very homogenous country, and all people living in Denmark 
have equal access to health care services, adding to the credibility of the registries 
used in this study, as it limits the potential for a socioeconomic bias. Moreover, the 
validity of the registries from Statistics Denmark used in the present study is 
considered high (140,160–163). Another strength of study 1 is that several co-
morbidities were included in the statistical models and actually changed the 
outcome of the comparison between patients who did or did not receive HBO 
treatment. In the Kaplan-Maier plot, a statistically significant difference was 
observed between the survival curves (Figure 4, Study 1); however, this difference 
disappeared after adjustment for co-morbidities in the Cox model (Figure 5, Study 
1). 
One of the main limitations of study 1 is that it was a registry-based retrospective 
study, and therefore we were unable to draw any conclusions regarding causality of 
the factors investigated, but only described associations. Another limitation of this 
study is the lack of clinical data for HbCO values, lactate levels, electrolyte levels, 
cardiac rhythm, and blood pressure. The inclusion of these data in the Cox model 
might have increased the accuracy of our estimates, which might have contributed 
to a better understanding of how these clinical parameters influence mortality and 
morbidity. Unfortunately, this information was not accessible. In addition, in the 
statistical models, we were unable to ensure that other confounding factors, not 
included/unknown, might have had influenced the results.  
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Studies 2 and 3 shares some strengths and limitations regarding the use of animals 
as substitute for humans in research. The main limitation of animal studies is the 
interpretation of how the results may translate to a clinical setting with human 
patients. We surmised that the use of a large animal model would provide us with 
results that are more translatable to humans than a model using rodents. We chose 
a porcine model for several reasons. Pigs are similar in size to humans and have a 
comparable anatomy and cardiac/pulmonary function (respiratory frequency, heart 
rate, blood pressure, arterial blood gas values, etc.) (164). The same instrumentation 
and monitoring devices can be used on animals and humans, which is an important 
factor when evaluating the feasibility of the experiments. Additionally, pigs have 
previously been used in studies exploring different aspects of applying ECMO 
technology to treat different conditions (165,166). However, some differences that 
may affect translation to human conditions must be considered. For example, a pre-
existing collateral coronary blood supply is not present in the pig heart (164).  
A comparison of the ECMO treatment with a group subjected to HBO treatment 
would have been valuable. However, this comparison was not possible considering 
the distance to the nearest hyperbaric chamber. For this reason, the results cannot 
be directly compared with results that would potentially be obtained when 
administering HBO therapy. 
Another major limitation is that neurological outcomes were not evaluated because 
biomarkers of neurological ischemia were not measured during the experiments and 
the animals were euthanized at the end of the experiments.  
In study 3, the pigs were placed on ECMO shortly after randomization (mean=4.3 
min). This would not have been possible in a real clinical setting. We designed the 
experiment in this way in order to gain the clearest possible insight into the potential 
effects of ECMO. In future studies a time delay could be inserted to simulate the 
duration of cannulation or cannulation could actually be performed once cardiac 
failure sets in. On the other hand our studies also revealed that ECMO could be used, 
even after a period of cardiac arrest, as the time spent on ventilator in the ventilator 
group delays the initiation of ECMO treatment.  
We decided that it would involve too high a risk for the medical staff and the crew 
onboard the Hercules aircraft, to perform the poisoning of the pig onboard. No 
immediate escape or access to non-toxic air would be possible in case of a major leak 
of CO into the cabin of the aircraft. Therefore, we decided to poison the pig in a 
hangar close to the runway. This, however, had the side effect, that we could not 
perform the experiment in the same manner as in study 2, where CO intoxication 
was increased gradually until cardiac failure. Instead, HbCO was kept at around 50% 
to ensure severe poisoning but not initiating cardiac failure, as this would 
compromise our attempt to perform the cannulation while airborne. In a clinical 
 
49 
setting, the drop in HbCO would also have been present during the transportation 
from a medical facility to Airfield. 
Due to the nature of this experiment, where multiple cooperating teams and a 
military aircraft were used, only one flight with the described setup of study 3 was 
possible during this PhD project. It would have improved credibility of the data, if 
multiple flights could have been performed, and further insight into the potential 
challenges of in-air cannulation might have been gained. Planning and execution of 
test flights are a demanding and costly task. A different solution would have been, 
using a hypobaric chamber for the tests. Though, as this is a feasibility study, several 
factors with influence on feasibility would have been hard to recreate in a hypobaric 
chamber; turbulence, vibration and G-forces. 
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7 CONCLUSIONS 
The work of this thesis resulted in improved knowledge regarding the epidemiology 
of CO poisoning in Denmark. A new treatment option in which ECMO was used was 
investigated using a porcine model. This treatment seemed promising, although 
further research is needed. In addition, a feasibility study was performed where the 
treatment methodology from Study 2 was implemented successfully during a flight 
with a fixed wing aircraft.  
The three studies included in this PhD thesis, lead to several important conclusions. 
In study 1, it was demonstrated that around 1,000 patients suffer from CO 
poisoning/smoke poisoning each year, and around 100 people die from this in 
Denmark. Treatment with HBO therapy was not associated with increased or 
decreased survival when taking co-morbidities, sex and age into account. The co-
morbidities that are associated with increased mortality, or the risk of being 
poisoned in the first place, are generally factors that affect cognitive or physical 
function i.e. age, alcohol abuse, psychiatric disease, arterial embolisms and 
cerebrovascular disease. Approximately 50% of those who died, committed suicide 
and in these cases, the preferred source of CO-exposure was from gas form and not 
from fire smoke. 
Study 2 demonstrated, in a porcine experimental model, superior survival using 
ECMO vs. normobaric oxygenation with 100% oxygen for CO poisoning with 
subsequent cardiogenic shock. It was also demonstrated that even in case of cardiac 
arrest, resuscitation efforts followed by ECMO treatment may secure survival, and 
that it was possible to achieve a significantly higher PaO2 using ECMO vs. ventilator 
with FiO2 at 100%. Cardiac failure was not a result of increased PVR. 
In study 3, it was demonstrated that it is feasible to transfer the findings from study 
2 to an aeromedical setting. Use of ECMO on a fixed wing aircraft to treat CO 
poisoning in a porcine model was possible. Cannulation and ECMO treatment was 
successfully performed, during cardiac arrest, while airborne.

 
53 
8 FUTURE PERSPECTIVES 
Altogether, the studies included in this PhD thesis have generated several questions 
for further research. 
Although a decreasing trend in the number of fatalities from CO poisoning has been 
observed each year, it is still a relatively frequent cause of hospitalization and leads 
to subsequent mortality and morbidity. The relationships between the co-
morbidities/CO poisoning and death established in this study provide information 
about which patient categories are at an increased risk of being poisoned and have 
the highest mortality. Using this information, preventive efforts may be established, 
such as the installation of smoke/CO detectors, and close follow up following 
discharge should be considered. In Study 1, no survival benefits of HBO treatment 
were observed. Further studies examining this topic are required to clarify the 
effects of HBO. Since a substantial selection bias is hard to avoid because HBO 
treatment is only available at one site in Denmark. Future studies should employ a 
randomized controlled trial design and include patients throughout Denmark. The 
addition of clinical data would improve the possibilities to draw a solid conclusion.  
The future use of ECMO for CO poisoned patients with cardiac failure seems 
promising, although additional research is required. As several limitations in 
transferring knowledge obtained from animal studies to the treatment of human 
patients exist, a study protocol that involves human victims of CO poisoning must be 
designed. However, additional animal studies may be needed prior to conducting 
human trials. A study assessing neurological outcomes would be beneficial to avoid 
resuscitating patients to a poor quality of life, which is associated with severe 
ischemic brain injury. Emerging biomarkers for cerebral injury, such as neuron-
specific enolase or S100b, might be beneficial for these experiments (167). 
Additionally, several possibilities exist to optimize the ECMO protocol before testing 
it in a hospital setting. When the patient is connected to extracorporeal circulation, 
the blood can be treated to facilitate a faster reduction in HbCO levels. Would 
illumination with a strong light source with wavelength between 532-628 nm be an 
option (168)? These wavelengths have poor penetration in tissue, but extracorporeal 
use would bypass this limitation. Would the addition of CO2 to the oxygenator be 
beneficial (169)? Would simultaneous treatment with antioxidants be effective? 
Could ECMO and HBO be administered at the same time? All these questions will 
inspire several additional research projects. 
The possibilities of using ECMO during long-distance transport in fixed wing aircrafts 
for CO poisoned victims may facilitate the safer transport of these patients from the 
area of intoxication to a capable health care facility that may offer HBO, such as in a 
military setting in which smoke/CO poisoned victims are transported from an area 
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of conflict or a situation with a massive number of casualties, i.e., a nightclub fire 
(154). The potential to perform cannulation while airborne might allow the transport 
of critical patients who otherwise would have been ruled too unstable to move 
because ECMO can be used as a backup strategy. The use of ECMO treatment as a 
rescue therapy might also be beneficial when transporting patients with other 
injuries that impair cardiopulmonary functions, i.e., blast-injured lungs, ARDS, 
pulmonary embolism and hypothermia. In a military setting, the implementation of 
ECMO may shorten the evacuation chain by one or two steps, and thus forward 
medevac and tactical medevac would be combined into one flight to a Role 4/5 
health care facility. During this flight, en route damage control surgery may be 
performed with the possibility of administering ECMO as a treatment option.  
Clearly, more research in this area is required and, although some disadvantages 
exist, we suggest the use of a hypobaric chamber to simulate pressure conditions at 
altitude and make further studies more feasible. 
Altogether, this PhD thesis reveals the substantial potential for further research in 
the field of CO poisoning, with promising signs that additional research may lead to 
the development of improved treatments in the future.  
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